🇺🇸 Labetolol in United States
75 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 28 March 2025 – 28 March 2026
- Total reports: 75
Most-reported reactions
- Hypotension — 9 reports (12%)
- Nausea — 9 reports (12%)
- Diarrhoea — 8 reports (10.67%)
- Fatigue — 8 reports (10.67%)
- Acute Kidney Injury — 7 reports (9.33%)
- Anaemia — 7 reports (9.33%)
- Drug Ineffective — 7 reports (9.33%)
- Dyspnoea — 7 reports (9.33%)
- Renal Failure — 7 reports (9.33%)
- Blood Glucose Increased — 6 reports (8%)
Other Other approved in United States
Frequently asked questions
Is Labetolol approved in United States?
Labetolol does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Labetolol in United States?
Zagazig University is the originator. The local marketing authorisation holder may differ — check the official source linked above.